Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Changing emphasis on research and development (R&D):

This article was originally published in Clinica

Executive Summary

As treatment decisions are made increasingly on a cost-benefit basis, R&D must address the criteria on which product use will be assessed. Writing in Health-Care Focus, the newsletter of UK industry association ABHI, Oliver Wells points out that "if industry is to maximise its potential, we have to understand - and get involved in - the R&D that is relevant to our customers, and the basis on which they will make treatment decisions in future". Mr Wells is the ABHI representative on the NHS R&D National Forum which was set up earlier this year to bring together major funders of health-related research (see Clinica No 635, p 3).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel